These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9653595

  • 1. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, Panelo AA, Kim DK, Embong M.
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA.
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B, Piñol C.
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J.
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J, Spengler M.
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K.
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF, Shapiro JA, Seaton TB.
    Arch Intern Med; 1994 Nov 14; 154(21):2442-8. PubMed ID: 7979840
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PROTECT interim results: a large multicenter study of patients with type II diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies.
    Baron A, Neumann C.
    Clin Ther; 1997 Nov 14; 19(2):282-95. PubMed ID: 9152567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.